Results for dissolution therapy translation from Danish to Dutch

quake: dissolution of eternity
quake: dissolution of eternity

ce gie est en voie de dissolution.
ce gie est en voie de dissolution.

safety studies for gene therapy products.
safety studies for gene therapy products.

b01ad thrombolytic therapy for acute myocardial infarction
b01ad thrombolytic therapy for acute myocardial infarction

jo5ag03 combination therapy of hiv- 1 infected patients
jo5ag03 combination therapy of hiv-1 infected patients

n03a adjunctive therapy in the partial onset seizures in epilepsy
- n03a - adjunctive therapy in the partial onset seizures in epilepsy

a16ax03 adjunctive therapy in the chronic management of urea cycle disorders
a16ax03 adjunctive therapy in the chronic management of urea cycle disorders

a) cattle b) adjunctive therapy in acute respiratory infection
a) cattle b) adjunctive therapy in acute respiratory infection

concept paper on the development of a points to consider on xenogeneic cell therapy
points to consider on xenogeneic cell therapy note for guidance on the production and

long- term replacement therapy in patients with a confirmed diagnosis of fabry disease
long-term replacement therapy in patients with a confirmed diagnosis of fabry disease

a16ax06 ttreatment of mild to moderate type 1 gaucher disease when enzyme replacement therapy is unsuitable
a16ax06 ttreatment of mild to moderate type 1 gaucher disease when enzyme replacement therapy is unsuitable

punkter, som bør tages i betragtning helicobacter pylori eradication therapy wording in selected spc sections
informatiedocumenten helicobacter pylori eradication therapy wording in selected spc sections

single- dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:
single-dose fluorchinolone therapy of acute uncomplicated urinary tract infection in women:

boehringer ingelheim l03aa international gmbh adjunct therapy de to surgery for irresectable soft tissue sarcoma of the limbs, to prevent or delay amputation
boehringer ingelheim l03aa international gmbh adjunct therapy de to surgery for irresectable soft tissue sarcoma of the limbs, to prevent or delay amputation

titel på dokumentet antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
titel document antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy

der blev ligeledes fundet en reduktion i træthed, målt ved hjælp af ” functional assessment of cancer therapy- fatigue te
d was er een significante afname van de noodzaak tot transfusie en een verbetering van de hemoglobinerespons (p < 0,001). verbetering van vermoeidheid zoals gemeten via de “ functional

need for post- marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure
need for post-marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure

h01ax (proposed) treatment of patients with acromegaly who had an inadequte response to surgery and/ or radiation therapy and who did not respond to treatment with somatostatin analogues
h01ax (proposed) treatment of patients with acromegaly who had an inadequte response to surgery and/or radiation therapy and who did not respond to treatment with somatostatin analogues

* i følge national cancer institute of canada clinical trial group (ncic ctg) common toxicity criteria (version 1) eller common terminology criteria for adverse events (ctcae) fra cancer therapy evaluation program, us national cancer institute, version 3, 0.
* volgens de “ national cancer institute of canada clinical trial group” (ncic ctg) common toxicity criteria (versie 1) van de “ common terminology criteria for adverse events” (ctcae) van het “ cancer therapy evaluation program, us national cancer institute, versie 3.0”.